Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2021 | 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Sales | 2,727 | 2,950 | 2,793 | 2,865 | 1,229 |
| Cost of Goods | 1,645 | 1,910 | 1,618 | 1,943 | 716 |
| Gross Profit | 1,082 | 1,040 | 1,175 | 922 | 513 |
| Operating Expenses | 7,399 | 6,546 | 7,114 | 8,833 | 5,431 |
| Operating Income | -6,317 | -5,506 | -5,939 | -7,911 | -4,918 |
| Interest Expense | 55 | 63 | 6 | 55 | 61 |
| Other Income | 73 | -405 | 13 | 12 | 77 |
| Pre-tax Income | -6,299 | -5,974 | -5,932 | -7,954 | -4,902 |
| Income Tax | N/A | N/A | N/A | 0 | 5 |
| Net Income Continuous | -6,299 | -5,974 | -5,932 | -7,954 | -4,907 |
| Net Income Discontinuous | 0 | 0 | -564 | -970 | N/A |
| Net Income | $-6,299 | $-5,974 | $-6,496 | $-8,924 | $-4,907 |
| EPS Basic Total Ops | -0.13 | -0.13 | -0.17 | -0.20 | -0.20 |
| EPS Basic Continuous Ops | -0.13 | -0.14 | -0.15 | -0.21 | -0.20 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | -0.01 | -0.03 | N/A |
| EPS Diluted Total Ops | -0.13 | -0.13 | -0.17 | -0.20 | -0.20 |
| EPS Diluted Continuous Ops | -0.13 | -0.14 | -0.15 | -0.21 | -0.20 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | -0.01 | -0.03 | N/A |
| EBITDA(a) | $-6,146 | $-5,810 | $-5,824 | $-7,761 | $-4,703 |